Telotristat in the management of carcinoid diarrhoea - Real world experience of patients from an ENETS Centre of Excellence in neuroendocrine tumors

#3301

Introduction: Carcinoid syndrome occurs in 20% patients, presenting with flushing, abdominal pain, diarrhoea, and wheeze. The standard of care for carcinoid syndrome is somatostatin analogues (SSAs) with add-on Creon, codeine and loperamide therapy. Nonetheless, half of patients experience debilitating diarrhoea. Telotristat-ethyl is a peripheral tryptophan-hydroxylase inhibitor approved for treatment of diarrhoea, supported by Phase-3 clinical trials.

Aim(s): We present our experience on effectiveness of Telotristat on carcinoid diarrhoea in the largest cohort of patients outside a clinical trial. The primary outcome was reduction in stool frequency (number/day) of >30%, as defined in most studies.

Materials and methods: Data was collected retrospectively from an electronic database. We included 31 patients (25M, 6F; Median age 69 (45-85) years) {study group} on Telotristat and 10 patients on maximum dose of 2 weekly SSAs but no Telotristat (6M, 4F; Median age 67 (49-79) years) {control group}.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Cianci N

Authors: Khanna A, Cianci N, Shah H, Chauhan J, Pipe M,

Keywords: Telotristat, carcinoid syndrome, somatostatin analogues, neuroendocrine tumor,